Investors

Financials & Filings

Filing date Form Description Filing Group View
4

Statement of changes in beneficial ownership of securities

3,4,5
8-K

Report of unscheduled material events or corporate event

Current Reports
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
424B3

Form of prospectus reflecting facts events constituting substantive change from last form

Registration Statements
8-K

Report of unscheduled material events or corporate event

Current Reports
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
4

Statement of changes in beneficial ownership of securities

3,4,5
3

Initial filing by director officer or owner of more than ten percent

3,4,5
EFFECT

EFFECT

Other
10-Q

Quarterly report which provides a continuing view of a company's financial position

Quarterly Filings
EX-101.LAB - XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
S-3/A

Pre-effective amendment to an S-3 filing

Registration Statements
CORRESP

CORRESP

Other

Data provided by Kaleidoscope.

GNI Group, Ltd. (2160:Tokyo) (“GNI Japan”) holds an indirect, controlling interest in Gyre Therapeutics, Inc. From time to time, GNI Japan will disclose historical and forward looking information, which will include information about our business. We may not have previously disclosed such information. Please refer to https://www.gnipharma.com/ir/yuho/ for GNI Japan’s Investor Information and Securities Reports.